SUZHOU, China, Oct. 5, 2022 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, has received IND clearance from U.S. Food and Drug Administration (FDA).